Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Halozyme Therapeutics Inc banner

Halozyme Therapeutics Inc
F:RV7

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
F:RV7
Watchlist
Price: 93.08 EUR 1.17%
Market Cap: €11.8B
Write Note Create Alert Ask AI

Wall St Price Targets

RV7 Price Targets Summary
Halozyme Therapeutics Inc

Wall Street analysts forecast RV7 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RV7 is 57.33 EUR with a low forecast of 47.57 EUR and a high forecast of 64.63 EUR.

RV7 Lowest Forecast
Wall Street Target
€47.57
-49% Downside
RV7 Average Forecast
Wall Street Target
€57.33
-38% Downside
RV7 Highest Forecast
Wall Street Target
€64.63
-31% Downside
Lowest Forecast
Price Target
47.57 EUR
49% Downside
Average Forecast
Price Target
57.33 EUR
38% Downside
Highest Forecast
Price Target
64.63 EUR
31% Downside
Halozyme Therapeutics Inc Competitors:
Price Targets

Revenue
Forecast

31% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
31% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 0%.

What are analyst estimates?

Gross Profit
Forecast

29% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
29% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 29%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

The compound annual growth rate for Operating Income over the next 8 years is -7%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
N/A
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 48%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
N/A
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 9%.

What are analyst estimates?

Continue RV7 Research

Summary
RV7 intrinsic value, competitors valuation, and company profile.
DCF Valuation
RV7 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RV7 stock valuation using valuation multiples.
Wall St Estimates
RV7 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RV7 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Halozyme Therapeutics Inc listings:
NASDAQ • USD
HALO
 SWB • EUR
RV7
 LSE • USD
0J2O
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RV7's stock price target?
Price Target
57.33 EUR

According to Wall Street analysts, the average 1-year price target for RV7 is 57.33 EUR with a low forecast of 47.57 EUR and a high forecast of 64.63 EUR.

What is the Revenue forecast for Halozyme Therapeutics Inc?
Projected CAGR
0%

Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 0%.

What is the Operating Income forecast for Halozyme Therapeutics Inc?
Projected CAGR
-7%

The compound annual growth rate for Operating Income over the next 8 years is -7%.

What is the Pre-Tax Income forecast for Halozyme Therapeutics Inc?
Projected CAGR
48%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 48%.

What is the Net Income forecast for Halozyme Therapeutics Inc?
Projected CAGR
9%

The compound annual growth rate for Net Income over the next 8 years is 9%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.